Trials / Terminated
TerminatedNCT02008513
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
A Randomized, Controlled, Parallel Group, Double-blind, Multi-centre, Phase IIb Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in the AFFITOPE® AD02 Phase II Study AFF006.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Affiris AG · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a follow-up study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations in patients with Alzheimer's disease. Patients, who have already participated in AFF006 will be involved in 27 study sites in Europe. Duration of patient's participation in the clinical trial is 19 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AFFITOPE® AD02 | |
| BIOLOGICAL | Placebo |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-12-11
- Last updated
- 2015-06-24
Locations
27 sites across 6 countries: Austria, Croatia, Czechia, France, Germany, Slovakia
Source: ClinicalTrials.gov record NCT02008513. Inclusion in this directory is not an endorsement.